ChiCTR1900024433
尚未开始
/
/
/
2019-07-11
/
/
subjective cognitive decline
Can increasing participation in habitual intellectual activities enhance functional connectivity of default mode network in community-living Chinese adults with subjective cognitive decline? A randomized controlled trial.
Can increasing participation in habitual intellectual activities enhance functional connectivity of default mode network in community-living Chinese adults with subjective cognitive decline? A randomized controlled trial.
1. To examine the effect of doubling usual practice of calligraphy on global cognitive function in people with subjective cognitive decline; 2. To examine the effect of doubling usual practice of calligraphy on functional connectivity within default mode network in people with subjective cognitive decline; and 3. To examine the correlation between cognitive and functional connectivity changes.
随机抽样
Ⅱ期
In the randomization procedure, each participant will be assigned a special code generated by a computer. The statistician of the department will perform all the randomization and will not be involved in enrollment or outcome assessment.
Not stated
Research Grants Council
/
56
/
2019-09-01
2021-08-31
/
Community-living Chinese individuals aged 55 to 75 years old with subjective cognitive decline will be recruited through elderly social centres in Hong Kong;
登录查看non-Chinese ethnicity; living in care homes; having history of stroke, traumatic brain injury, Parkinsons disease, mild cognitive impairment, or clinical dementia; taking drugs that affect cognition (e.g. benzodiazepines, anti-dementia medication, etc.); having history of depression, bipolar affective disorder, psychosis, or substance abuse; already attending other cognitive intervention programs or having regular participation in painting (at least one hour of painting per week); and significant impairments in communication or writing.;
登录查看Research Grants Council
/
diabetes 埃诺格鲁肽 SLIMMER
医药笔记2025-06-22
遗传性血管性水肿 III期 BD项目
美柏资本2025-06-22
ADA GIPR PCSK9
信达生物2025-06-22
diabetes 埃诺格鲁肽 内分泌学
先为达生物2025-06-22
PDL1 三阴性乳腺癌 atezolizumab
BioArtMED2025-06-21
EGFR 结直肠癌 JMT101
石药集团2025-06-21
糖尿病 GLP-1/GIP
恒瑞医药2025-06-21
肥胖 Wegovy
一度医药2025-06-21